WOODCLIFF LAKE, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that it will deliver a Trial in Progress presentation...
WOODCLIFF LAKE, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that data from the Company's Phase III trial...
-- BARHEMSYS® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration (œFDA) for rescue treatment of postoperative nausea and vomiting (œPONV)...
MARLBOROUGH, Mass. & PRINCETON, N.J.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in SEP380-301, a Phase 3 clinical study evaluating non-racemic amisulpride (SEP-4199) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression). Non-racemic amisulpride is being jointly developed and commercialized as part of a collaboration between Sunovion, its parent company Sumitomo Dainippon Pharma and Otsuka Pharmaceutical Co., Ltd.
NEW YORK--(BUSINESS WIRE)--LB Pharmaceuticals Inc, (“LB”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, announced today that the full results of a PET study of LB-102 (a N methylated version of the well-known and highly effective antipsychotic amisulpride), its lead compound to treat schizophrenia, have been presented at the 60th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held from December 5-8 in San Juan, Puerto Rico.
Biopharmaceutical company Acacia Pharma Group plc (Acacia Pharma) has announced that its Marketing Authorisation Application (MAA) for BARHEMSYS® (amisulpride injection) has been submitted and validated, and is now under formal review in major European markets. The review is forecasted to be completed by 2022.
Cambridge, UK and Indianapolis, US – 29 September 2021: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces that its Marketing Authorization Application (MAA) for BARHEMSYS® (amisulpride injection) has been submitted, validated and is now under formal review in major European markets. The review process is expected to be completed by Q3/2022.
Cambridge, UK and Indianapolis, US – 24 August 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces today that BARHEMSYS® (amisulpride injection) has been launched and is now commercially available in the US for order and delivery to customers through major wholesalers and specialty distributors. BARHEMSYS was approved by the US Food and Drug Administration (FDA) for the treatment and prevention of postoperative nausea & vomiting (PONV) on 26 February 2020.
Third time’s the charm for Acacia Pharma. The Cambridge, UK-based company on Thursday finally secured FDA approval for its treatment for patients with postoperative nausea & vomiting (PONV), who are symptomatic despite having received prophylactic treatment.
Will three be the charm for biotech Acacia and its drug candidate for postoperative nausea and vomiting? With a new contract manufacturer on board following two manufacturing-related denials by the FDA, the drugmaker said it has won its third action date, which is set for early in 2020